*Corresponding author:Michael Saul Lundin, Michigan State university, West Bloomfield, Michigan
Received: August 02, 2018; Published: August 09, 2018
To view the Full Article Peer-reviewed Article PDF
Pooled immunoglobulin (Ig) is a scarce and expensive resource, hypertension is the leading cause of death worldwide (as of 2010)  as the new blood pressure guidelines in 2017 make note of , and there is something that can be done to address both. In this article, we summarize the salient developments in the treatment of hypertension as well as put forward the hypothesis that employing thiazides in patients on chronic Ig replacement therapy may provide the dual benefit of treating blood pressure as well as increasing plasma concentration of immunoglobulins. Furthermore, there may be a side benefit to public health by increasing the supply of pooled immunoglobulin.
Keywords: Blood Pressure; Intervention; Salient Developments; Pooled Immunoglobulin; Systolic; Cardiovascular; Diabetes Mellitus; Chronic Kidney Disease; Thiazides; Diastolic; Hypertension